Serology testing is an important tool for monitoring the evolution of an outbreak. Serology tests that detect neutralizing antibodies are particularly useful for evaluating vaccine-induced protective immunity. As new SARS-CoV-2 variants emerge with mutations in the spike S protein, their potential to become “escape mutants” and negatively impact vaccine efficacy needs to be evaluated through neutralization testing.
Meridian’s new panel of SARS-CoV-2 mutant recombinant antigens represent the major circulating mutant strains (UK B.1.1.7, SA B.1.351, Brazil P.1 and California L425R mutant) and are suitable for use in neutralization studies and as controls in serology assays. They complement the existing range of high-performing SAR-CoV-2 wild-type antigens, several of which are in current EUA approved COVID-19 IgG/IgM serology tests.
All antigens are expressed in insect cells unless otherwise indicated.